~~<i id='2A2AF29487'><strike id='2A2AF29487'><tt id='2A2AF29487'><pre id='2A2AF29487'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：fashion 2025-09-30 13:53:50 Page View：83259

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Can Threads overtake X, formerly known as Twitter? Experts weigh in.
Next article： Moonlake's readout produced a cash windfall. Risks remain

comprehensive

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Are infertility treatments 'essential' during the Covid

Aninfertilityspecialistspointstoahumaneggcellafterinsemination.IVANCOURONNE/AFPviaGettyImagesAstheCo

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

9:45AttorneyforformerPresidentDonaldTrump,JohnLauro,speakstoABC'sGeorgeStephanopoulosonAug.6,2023,in